Severe Opioid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Severe opioid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Severe Opioid Today - Breaking & Trending Today

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

/PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office. ....

United Kingdom , United States , United Arab Emirates , David Belian , Steve Weiss , Brian Hoffmann , Kenneth Stammen , Rahul Gupta , Kelsey Caitlin Bates , Office Of National Drug Control , Hikma Community Health , Prnewswire Hikma Pharmaceuticals , Community Strategy , Us Communications , Hikma Pharmaceuticals United States Inc , Hikma Specialty United States Inc , Public Affairs , Continues Hikma , National Drug Control Policy , White House Office , Unity Agenda , President Biden , Black Community Strategy Director , Regional Coordinator , Harm Reduction , Hikma Community ,

Hikma marks two-year anniversary of KLOXXADO® launch by surpassing 375,000 doses donated in the US

/PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that on the two-year anniversary of its launch, it has. ....

United Arab Emirates , United Kingdom , United States , City Of , David Belian , Brian Hoffmann , Susan Ringdal , Steve Weiss , Hikma Pharmaceuticals United States Inc , Emergent Operations Ireland , Hikma Community Health , Public Affairs , Naloxone Network Buyers Club , Hikma Pharmaceuticals , Us Communications , Pay Assistance Program , Washington Post , Community Programs , Prnewswire Hikma Pharmaceuticals , Hikma Specialty United States Inc , Global Affairs , White House Office Of National Drug Control , White House Office , National Drug Control Policy , Opioid Safety , For The People ,

Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg

Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride) nasal spray 8mg
Important new option for reversing opioid overdoses
News provided by
Share this article
Share this article
LONDON, April 30, 2021 /PRNewswire/ Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces the approval of KLOXXADO
TM (naloxone hydrochloride) nasal spray 8mg, by the US Food and Drug Administration (FDA) for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
KLOXXADO
TM contains twice as much naloxone per spray as Narcan
® Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic. ....

United Arab Emirates , United States , United Kingdom , City Of , Steve Weiss , Susan Ringdal , David Belian , Brian Hoffmann , Drug Administration , Advisory Committee , Global Affairs , Hikma Pharmaceuticals United States Inc , Community Settings , Us Communications , Public Affairs , Hikma Specialty United States Inc , Hikma Pharmaceuticals , Pharma Operations , Nasal Spray , Hikma Pharmaceuticals United States , Strategic Planning , Middle East , North Africa , Nasal Spray Important Safety , Recurrent Respiratory , Central Nervous System ,